Major tobacco companies are increasingly relying on nicotine pouches to offset declining cigarette sales, citing rapid growth and higher profit margins. Investors are tracking the performance of brands like Philip Morris International’s Zyn and British American Tobacco’s Velo as the industry attempts to expand these products beyond established markets in the United States and Scandinavia. Industry executives describe the pouches—small nicotine packets placed under the lip that do not contain tobacco—as a primary growth engine that could potentially replace cigarettes in the long term.
British American Tobacco (BAT) reported that nicotine pouch volumes in Asia, the Middle East, and Africa rose 27.5% to approximately 700 million units in the first half of 2026. However, this figure remains significantly lower than the 3 billion pouches sold in the company’s U.S. and European segments. While Philip Morris International (PMI) noted that oral nicotine products currently represent only 2.6% of its total volumes, the company reported that its U.S. pouch business generated eight times the gross profit per thousand units compared to its international cigarette business in 2024.
Despite the growth, the category faces regulatory and cultural challenges. The World Health Organization (WHO) has called for tighter controls, stating that uptake is driven by aggressive marketing and high nicotine strengths that appeal to new users. As of May 2026, the WHO reported that 160 countries lacked specific regulations for nicotine pouches. In response to health and youth-uptake concerns, France has banned the products, Finland has mandated plain packaging, and both Britain and the European Union are currently tightening regulations.
For the average consumer, this transition may result in a change in how nicotine is accessed and used. Because pouches do not produce smoke or vapor, they can be used in locations where cigarettes and e-cigarettes are restricted, potentially altering daily habits for nicotine users. However, the cost and availability of these products will depend heavily on local laws. Residents in countries like France already face total bans, while those in Britain and the EU will notice stricter marketing rules and packaging requirements as governments attempt to curb youth usage.
The expansion of nicotine pouches also creates a regulatory precedent for how non-combustible products are treated compared to traditional tobacco. While the U.S. Food and Drug Administration (FDA) has noted that switching completely to alternatives may reduce health risks for smokers, health experts emphasize that pouches are not risk-free. The long-term impact on public health policy will be determined by whether these products serve as a tool for smoking cessation or as a gateway for new users. The next significant milestones include the implementation of new regulatory frameworks in the EU and the monitoring of sales growth in non-traditional markets throughout late 2026.